UnitedHealth Group and Merck & Co are both in line for exits as Decipher Biosciences files for a $100m initial public offering.

Yale-linked Vera has rebranded from Trucode Gene Repair and will use the money to move towards clinical trials.

Vera has picked up series C cash from investors including GV and Alexandria Venture Investments to help progress its Merck Group-licensed autoimmune disease drug candidate through clinical trials.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.

Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.

The KU Leuven spinout has completed another tranche of funding for its series B round featuring investments from the university.

Amgen and Pfizer-backed oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.

Novo and Pfizer are among the investors set to exit the cancer therapy developer, which has set a $100m target for its initial public offering.

GV-backed Aledade has secured series D funding at a $2.2bn post-money valuation to build out the business model for its primary care network.